Neurobiology of Aging
Volume 29, Issue 8 , Pages 1167-1176 , August 2008

A SNP in the ACT gene associated with astrocytosis and rapid cognitive decline in AD

  • O. Belbin

      Affiliations

    • Division of Clinical Chemistry, Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK
    • ,
  • J.L. Dunn

      Affiliations

    • School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, UK
    • ,
  • S. Chappell

      Affiliations

    • Division of Clinical Chemistry, Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK
    • ,
  • A.E. Ritchie

      Affiliations

    • Division of Clinical Chemistry, Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK
    • ,
  • Y. Ling

      Affiliations

    • Division of Clinical Chemistry, Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK
    • ,
  • L. Morgan

      Affiliations

    • Division of Clinical Chemistry, Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK
    • ,
  • A. Pritchard

      Affiliations

    • Department of Human Genetics, G Floor CBCRC Building, Queensland Institute of Medical Research, 300 Herston Road, Herston, Brisbane 4006, Australia
    • Present address: Department of Human Genetics, Queensland Institute of Medical Research, Herston, QLD 4006, Australia.
    • ,
  • D.R. Warden

      Affiliations

    • OPTIMA, Oxford Centre for Gene Function, Department of Physiology, Anatomy & Genetics, Oxford OX1 3PT, UK
    • ,
  • C.L. Lendon

      Affiliations

    • Department of Human Genetics, G Floor CBCRC Building, Queensland Institute of Medical Research, 300 Herston Road, Herston, Brisbane 4006, Australia
    • Present address: Department of Human Genetics, Queensland Institute of Medical Research, Herston, QLD 4006, Australia.
    • ,
  • D.J. Lehmann

      Affiliations

    • OPTIMA, Oxford Centre for Gene Function, Department of Physiology, Anatomy & Genetics, Oxford OX1 3PT, UK
    • ,
  • D.M.A. Mann

      Affiliations

    • Greater Manchester Neurosciences Centre, University of Manchester, Manchester M6 8HD, UK
    • ,
  • A.D. Smith

      Affiliations

    • OPTIMA, Oxford Centre for Gene Function, Department of Physiology, Anatomy & Genetics, Oxford OX1 3PT, UK
    • ,
  • N. Kalsheker

      Affiliations

    • Division of Clinical Chemistry, Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK
    • ,
  • K. Morgan

      Affiliations

    • Division of Clinical Chemistry, Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 115 8230724; fax: +44 115 9709167.

Received 15 November 2006 ,Revised 19 December 2006 ,Accepted 10 February 2007.

References 

  1. Abraham CR, Selkoe DJ, Potter H. Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell. 1988;52:487–501
  2. Baker C, Nielsen HM, Minthon L, Wright HT, Chappell S, Okyere J, et al. Effects of Alzheimer's peptide and alpha1-antichymotrypsin on astrocyte gene expression. Neurobiol. Aging. 2007;28:51–61
  3. Bao JJ, Sifers RN, Kidd VJ, Ledley FD, Woo SL. Molecular evolution of serpins: Homologous structure of the human alpha 1-antichymotrypsin and alpha 1-antitrypsin genes. Biochemistry. 1987;26:7755–7759
  4. Bertram, L., Tanzi, R. E. (2004). Alzheimer's disease: One disorder, too many genes? Hum. Mol. Genet. ddh077.
  5. Chandra T, Stackhouse R, Kidd VJ, Robson KJ, Woo SL. Sequence homology between human alpha 1-antichymotrypsin, alpha 1-antitrypsin, and antithrombin iii. Biochemistry. 1983;22:5055–5061
  6. Chappell S, Guetta-Baranes T, Batowski K, Yiannakis E, Morgan K, O’Connor C, et al. Haplotypes of the alpha-1 antitrypsin gene in healthy controls and z deficiency patients. Hum. Mutat. 2004;24:535–536
  7. Chappell S, Daly L, Morgan K, Guetta Baranes T, Roca J, Rabinovich R, et al. Cryptic haplotypes of serpina1 confer susceptibility to chronic obstructive pulmonary disease. Hum. Mutat. 2006;27:103–109
  8. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature. 1992;360:672–674
  9. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921–923
  10. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet. Epidemiol. 2003;25:115–121
  11. Eriksson S, Janciauskiene S, Lannfelt L. Alpha 1-antichymotrypsin regulates alzheimer beta-amyloid peptide fibril formation. Proc. Natl. Acad. Sci. USA. 1995;92:2313–2317
  12. Ezquerra M, Blesa R, Tolosa E, Ballesta F, Oliva R. Alpha-antichymotrypsin gene polymorphism and risk for Alzheimer's disease in the spanish population. Neurosci. Lett. 1998;240:107–109
  13. Fraser PE, Nguyen JT, McLachlan DR, Abraham CR, Kirschner DA. Alpha 1-antichymotrypsin binding to alzheimer a beta peptides is sequence specific and induces fibril disaggregation in vitro. J. Neurochem. 1993;61:298–305
  14. Haines JL, Pritchard ML, Saunders AM, Schildkraut JM, Growdon JH, Gaskell PC, et al. No genetic effect of alpha1-antichymotrypsin in alzheimer disease. Genomics. 1996;33:53–56
  15. HapMap CI. A haplotype map of the human genome. Nature. 2005;437:1299–1320
  16. Itabashi S, Arai H, Matsui T, Matsushita S, Muramatsu T, Higuchi S, et al. Absence of association of alpha1-antichymotrypsin polymorphisms with Alzheimer's disease: a report on autopsy-confirmed cases. Exp. Neurol. 1998;151:237–240
  17. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of a beta 42(43) and a beta 40 in senile plaques with end-specific a beta monoclonals: evidence that an initially deposited species is a beta 42(43). Neuron. 1994;13:45–53
  18. Janciauskiene S, Eriksson S, Wright HT. A specific structural interaction of Alzheimer's peptide a beta 1-42 with alpha 1-antichymotrypsin. Nat. Struct. Biol. 1996;3:668–671
  19. Janciauskiene S, Rubin H, Lukacs CM, Wright HT. Alzheimer's peptide abeta1-42 binds to two beta-sheets of alpha1-antichymotrypsin and transforms it from inhibitor to substrate. J. Biol. Chem. 1998;273:28360–28364
  20. Kamboh MI, Sanghera DK, Ferrell RE, DeKosky ST. Apoe*4-associated Alzheimer's disease risk is modified by alpha 1-antichymotrypsin polymorphism. Nat. Genet. 1995;10:486–488
  21. Kienlen-Campard P, Miolet S, Tasiaux B, Octave JN. Intracellular amyloid-beta 1-42, but not extracellular soluble amyloid-beta peptides, induces neuronal apoptosis. J. Biol. Chem. 2002;277:15666–15670
  22. Kordula T, Rydel RE, Brigham EF, Horn F, Heinrich PC, Travis J. Oncostatin m and the interleukin-6 and soluble interleukin-6 receptor complex regulate alpha1-antichymotrypsin expression in human cortical astrocytes. J. Biol. Chem. 1998;273:4112–4118
  23. Kordula T, Bugno M, Rydel RE, Travis J. Mechanism of interleukin-1- and tumor necrosis factor alpha-dependent regulation of the alpha 1-antichymotrypsin gene in human astrocytes. J. Neurosci. 2000;20:7510–7516
  24. Lamb H, Christie J, Singleton AB, Leake A, Perry RH, Ince PG, et al. Apolipoprotein E and alpha-1 antichymotrypsin polymorphism genotyping in Alzheimer's disease and in dementia with lewy bodies. Distinctions between diseases. Neurology. 1998;50:388–391
  25. Lehmann DJ, Williams J, McBroom J, Smith AD. Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer's disease and to identify high-risk subgroups. Neuroscience. 2001;108:541–554
  26. Licastro F, Pedrini S, Ferri C, Casadei V, Govoni M, Pession A, et al. Gene polymorphism affecting alpha1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. Ann. Neurol. 2000;48:388–391
  27. Licastro F, Chiappelli M, Grimaldi LM, Morgan K, Kalsheker N, Calabrese E, et al. A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer's disease. Neurobiol. Aging. 2005;26:449–453
  28. Ma J, Yee A, Brewer HB, Das S, Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of alzheimer beta-protein into filaments. Nature. 1994;372:92–94
  29. Ma J, Brewer HB, Potter H. Alzheimer a beta neurotoxicity: Promotion by antichymotrypsin, apoe4; inhibition by a beta-related peptides. Neurobiol. Aging. 1996;17:773–780
  30. Martins CA, Oulhaj A, de Jager CA, Williams JH. Apoe alleles predict the rate of cognitive decline in alzheimer disease: a nonlinear model. Neurology. 2005;65:1888–1893
  31. Mirra SS, Hart MN, Terry RD. Making the diagnosis of Alzheimer's disease. A primer for practicing pathologists. Arch. Pathol. Lab. Med. 1993;117:132–144
  32. Morgan K, Licastro F, Tilley L, Ritchie A, Morgan L, Pedrini S, et al. Polymorphism in the alpha(1)-antichymotrypsin (ACT) gene promoter: effect on expression in transfected glial and liver cell lines and plasma ACT concentrations. Hum. Genet. 2001;109:303–310
  33. Mucke L, Yu GQ, McConlogue L, Rockenstein EM, Abraham CR, Masliah E. Astroglial expression of human alpha(1)-antichymotrypsin enhances alzheimer-like pathology in amyloid protein precursor transgenic mice. Am. J. Pathol. 2000;157:2003–2010
  34. Murphy GM, Sullivan EV, Gallagher-Thompson D, Thompson LW, van Duijn CM, Forno LS, et al. No association between the alpha 1-antichymotrypsin a allele and Alzheimer's disease. Neurology. 1997;48:1313–1316
  35. Nagy Z, Esiri MM, Hindley NJ, Joachim C, Morris JH, King EM, et al. Accuracy of clinical operational diagnostic criteria for Alzheimer's disease in relation to different pathological diagnostic protocols. Dement. Geriatr. Cogn. Disord. 1998;9:219–226
  36. Nilsson LN, Bales KR, DiCarlo G, Gordon MN, Morgan D, Paul SM, et al. Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 2001;21:1444–1451
  37. Nilsson LN, Das S, Potter H. Effect of cytokines, dexamethasone and the a/t-signal peptide polymorphism on the expression of alpha(1)-antichymotrypsin in astrocytes: significance for Alzheimer's disease. Neurochem. Int. 2001;39:361–370
  38. Nilsson LNG, Arendash GW, Leighty RE, Costa DA, Low MA, Garcia MF, et al. Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. Neurobiol. Aging. 2004;25:1153–1167
  39. Pasternack JM, Abraham CR, Van Dyke BJ, Potter H, Younkin SG. Astrocytes in Alzheimer's disease gray matter express alpha 1-antichymotrypsin mrna. Am. J. Pathol. 1989;135:827–834
  40. Pinheiro JBD. Mixed-Effects Models in s and s-Plus. Springer; 2000;
  41. Poller W, Faber JP, Weidinger S, Tief K, Scholz S, Fischer M, et al. A leucine-to-proline substitution causes a defective alpha 1-antichymotrypsin allele associated with familial obstructive lung disease. Genomics. 1993;17:740–743
  42. Roth MHF, Tym E, Mountjoy CJ. The Cambridge Examination for Mental Disorders of the Elderly. Camdex: Cambridge University Press; 1988;
  43. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am. J. Hum. Genet. 2002;70:425–434
  44. Sun YX, Wright HT, Janciauskiene S. Glioma cell activation by Alzheimer's peptide abeta1-42, alpha1-antichymotrypsin, and their mixture. Cell. Mol. Life Sci. 2002;59:1734–1743
  45. Talbot C, Houlden H, Craddock N, Crook R, Hutton M, Lendon C, et al. Polymorphism in aact gene may lower age of onset of Alzheimer's disease. Neuroreport. 1996;7:534–536
  46. Thaker U, McDonagh AM, Iwatsubo T, Lendon CL, Pickering-Brown SM, Mann DM. Tau load is associated with apolipoprotein E genotype and the amount of amyloid beta protein, abeta40, in sporadic and familial Alzheimer's disease. Neuropathol. Appl. Neurobiol. 2003;29:35–44
  47. Thome J, Baumer A, Kornhuber J, Rosler M, Riederer P. Alpha-1-antichymotrypsin bi-allele polymorphism, apolipoprotein-E tri-allele polymorphism and genetic risk of Alzheimer's syndrome. J. Neural. Transm. Park Dis. Dement. Sect. 1995;10:207–212
  48. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu. Rev. Biochem. 1983;52:655–709
  49. Wang X, DeKosky ST, Luedecking-Zimmer E, Ganguli M, Kamboh IM. Genetic variation in alpha(1)-antichymotrypsin and its association with Alzheimer's disease. Hum. Genet. 2002;110:356–365
  50. Yoshiiwa A, Kamino K, Yamamoto H, Kobayashi T, Imagawa M, Nonomura Y, et al. Alpha 1-antichymotrypsin as a risk modifier for late-onset Alzheimer's disease in japanese apolipoprotein E epsilon 4 allele carriers. Ann. Neurol. 1997;42:115–117
  51. Zhang Y, Hayes A, Pritchard A, Thaker U, Haque MS, Lemmon H, et al. Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer's disease. Neurosci. Lett. 2004;362:99–102

PII: S0197-4580(07)00060-7

doi: 10.1016/j.neurobiolaging.2007.02.021

Neurobiology of Aging
Volume 29, Issue 8 , Pages 1167-1176 , August 2008

Article Tools

* Image Usage & Resolution